← FDA DRUG APPROVALS

FDA ANDA · ANDA203751

CLOPIDOGREL

Sponsor: AMNEAL PHARMS

APPLICATION
ANDA203751
TYPE
ANDA
ORIGINAL APPROVAL
2014-04-11
LATEST ACTION
2025-08-01
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

CLOPIDOGREL BISULFATEPrescription
CLOPIDOGREL BISULFATE EQ 75MG BASE · TABLET · ORAL

Approval history

2025-08-01Labeling · Supplement 10 · standardAP
2025-08-01Labeling · Supplement 9 · standardAP
2022-05-05Labeling · Supplement 8 · standardAP
2022-05-05Labeling · Supplement 7 · standardAP
2019-09-12Labeling · Supplement 4 · standardAP
2019-09-12Labeling · Supplement 2 · standardAP
2019-09-12Labeling · Supplement 5 · standardAP
2019-09-12Labeling · Supplement 3 · standardAP
2014-04-11UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →